ARWR News and Press, Arrowhead Pharmaceuticals Inc. From 03/08/24

- Preclinical data show ARO-DM1 reduces muscular DMPK expression and corrects spliceopathies, which could lead to improved muscle strength and function Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a double-blinded, place...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: TD Cowen's 44th Annual Health Care Conference – March 6, 2024 Type: Fireside Chat Presentation Date: March 6, 2024 Time: 9:10 a.m. ET L...

2024-02-29 02:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-25 06:30:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors may want to jump into oversold Russell 2000 stocks. For one, after a rough outing in 2023, smaller-cap stocks are starting to come back strong. In fact, since bottoming out aroun...

2024-02-06 21:28:05 ET Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2024 Earnings Conference Call February 6, 2024, 04:30 PM ET Company Participants Vince Anzalone - VP, IR Chris Anzalone - President & CEO Bruce Given - Chief Medical Scientist James Hamilton...

2024-02-06 17:17:51 ET Gainers: Fortinet ( FTNT ) +14% . Sonos ( SONO ) +12% . SolarEdge Technologies ( SEDG ) +8% . Tenable Holdings ( TENB ) +7% . Cirrus Logic. ( CRUS ) +6% . Losers: Mercury Systems  ( MRCY ) ...

2024-02-06 16:57:07 ET More on Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy Arrowhead Pharmaceuticals: Transition To Commercialization Arrowhead Pharmaceuticals: Balance Sheet Concern Needs To Be Addressed ...

2024-02-06 16:24:31 ET More on Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy Arrowhead Pharmaceuticals: Transition To Commercialization Arrowhead Pharmaceuticals: Balance Sheet Concern Needs To Be Addressed ...

- Conference Call and Webcast Today, February 6, 2024, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 first quarter ended December 31, 2023. The Company is hosting a conference call today, February 6, 2024, at 4:30 p.m....

2024-02-06 07:25:47 ET More on Eli Lilly Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value Biotech And Pharma Diversification Pays Off Eli Lilly: The Cupboard Is Fully Stocked Eli Lilly beats top-line and bottom-line estimates; ...